Based on data from approved PD-1 antibodies, these AEs most commonly include endocrinological alterations (e.g. hypothyroidism and hyperthyroidism), and gastrointestinal (e.g. colitis) and skin toxicities (e.g. rash) [10]. This evidence concerns the gene PDCD1 and hyperthyroidism.